Skip to main content
Louis Vignati, MD, Endocrinology, Indianapolis, IN

LouisVignatiMD

Endocrinology • Indianapolis, IN

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Vignati is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vignati's full profile

Already have an account?

  • Office

    8515 Olde Mill Circle West Dr
    Indianapolis, IN 46260
    Phone+1 317-254-1686

Summary

  • Dr. Louis Vignati received an undergraduate degree from the University of Pennsylvania, a graduate degree in organic chemistry from American University and a medical degree from Thomas Jefferson University. He completed his house staff training at the University of Vermont and Endocrine Fellowship at the Peter Bent Brigham Hospital and the Elliot P. Joslin Research Laboratory in Boston, Massachusetts.
    He served as an officer in the USPHS in the Toxicology Branch of the National Institute of Health for Occupational Safety and Health. Dr. Vignati was senior physician at the Joslin Diabetes Center in Boston, Massachusetts. Dr. Vignati has been a principal investigator for numerous clinical trials and co-investigator for the DCCT (Diabetes Control and Complications Trial.
    He was Distinguished Medical Fellow at Eli Lilly and Company and served as the Medical Director for development of early phase endocrine compounds. At Lilly he participated in the global development of therapies diabetes and obesity including Humalog, Recombinant Glucagon, and Forteo. Following his tenure at Lilly Dr. Vignati was Vice President, Medical of Marcadia Biotech until Roche acquired Marcadia. He served as the Vice president of Clinical development for Calibrium LLC. Currently is active as consultant for Pharmaceutical development.

Education & Training

  • American University
    American UniversityM.S., Organic Chemistry, 1966
  • University of Pennsylvania
    University of PennsylvaniaB.A., 1964
  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1975 - 1977
  • University of Vermont Medical Center
    University of Vermont Medical CenterResidency, Internal Medicine, 1973 - 1975
  • University of Vermont Medical Center
    University of Vermont Medical CenterInternship, Internal Medicine, 1970 - 1971
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1970

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1990 - 2025
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Research Fellowship United States Public Health Service, 1975
  • Meesy Foundation Scholarship Thomas Jefferson University, 1967

Publications & Presentations

PubMed

Journal Articles

  • Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans  
    B. Finan, T. Ma, N. Ottaway, T. D. Muller, K. M. Habegger, K. M. Heppner, H. Kirchner, J. Holland, J. Hembree, C. Raver, S. H. Lockie, D. L. Smiley, V. Gelfanov, B. Ya..., Sci. Transl. Med., 1/1/2013
  • Oral protein kinase C Beta inhibition using Ruboxistaurin: Efficacy, Safety, and Causes of Vision Loss Among 813 Patients (1,392 Eyes) with Diabetic Retinopathy in the...  
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC; for the PKC-DRS and PKC-DRS2 Study Groups, 1/20/2011
  • Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema Invest Ophthalmol  
    Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L; PKC-DRS2 Study Group, Vis Sci, 1/1/2009
  • Join now to see all

Books/Book Chapters

  • Phase III Clinical Studies Peptides: Chemistry, Structure and Biology 
    Chapter: Design of an Optimal Mealtime Insulin (Lys-Pro) and its Assessment 
    Anderson J, Chance R, Slieker L, Vignati L, DiMarchi R1996
  • Organ Transplantation Replacement 
    Chapter: Replacement of Pancreatic Function Through the Use of Mechanical or Electronic Devices 
    Vignati L, Edelman, SVEditors: Cerilli, J.1987
  • Joslins Diabetes Mellitus 
    Chapter: Exercise and Diet 
    Vignati L, Cunningham LNEdition 12th,1985
  • Join now to see all

Abstracts/Posters

  • Diabetic Macular Edema, Relationship of Visual Acuity to Involvement of the Center of the Macula
    Sheetz, Matthew J.; Aiello, Lloyd P.; Davis, Matthw D.; Milton, Roy C.; Arora, Vipin; Hu, Kuolung; Girach, Aniz;, Vignati, Louis, Diabetes, 1/1/2004
  • Diabetic Retinopathy and Macular Edema Progression Rates in Recent Placebo-Controlled Clinical Trials
    Davis, Matthew; Aiello, Lloyd; Milton, Roy; Sheetz, Matthew; Arora, Vipin; Vignati, Louis, PKC-DRS and PKC-DMES Study Groups, Diabetes, 1/1/2003
  • Ruboxistaurin (RBX) Mesylate Treatment in Patients with Diabetic Peripheral Neuropathy (DPN) Improves Clinical Global Impression (CGI) and Correlates with Change in Pa...
    Bastyr, Edward III; Price Karen; Skljarevski, Vladimir; Lledo Alberto; Vignati, Louis, Diabetes, 1/1/2003
  • Join now to see all

Other

  • Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy 
    A Girach, L P Aiello, R C Milton, M D Davis, R P Danis, X Zhi, M J Sheetz and L Vignati, Eye
    1/7/2008
  • Protein Conservation During Fasting: A Function of Triiodothyronine Levels: Transactions American Association of Physicians, Volume ICI 
    Vignati L, Finley R, Hagg S, Aoki TT
    1/1/1978

Dr. Louis Vignati, Dr. Louis Vignati, MD, Dr. L Vignati